BCLI - Brainstorm Cell Therapeutics Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
3.7300
-0.0400 (-1.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close3.7700
Open3.7700
Bid0.0000 x 2200
Ask0.0000 x 1200
Day's range3.6900 - 3.7700
52-week range2.9200 - 5.3500
Volume42,363
Avg. volume60,122
Market cap80.953M
Beta (3Y monthly)0.73
PE ratio (TTM)N/A
EPS (TTM)-0.8150
Earnings date8 Jul 2019 - 18 Jul 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.50
Trade prices are not sourced from all markets
  • Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
    Simply Wall St.2 months ago

    Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)

    Brainstorm Cell Therapeutics Inc.'s (NASDAQ:BCLI): Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to addressRead More...

  • Do Institutions Own Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shares?
    Simply Wall St.6 months ago

    Do Institutions Own Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shares?

    A look at the shareholders of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while Read More...

  • Simply Wall St.8 months ago

    Does Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Fall With The Market?

    If you’re interested in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock Read More...

  • Business Insider UK11 months ago

    BrainStorm will not provide ALS therapy under U.S. Right to Try act

    BrainStorm Cell Therapeutics Inc will not make its experimental stem cell treatment for neurodegenerative diseases available under the new U.S. "Right to Try" (RTT) act, citing a failure to find a way to enable all patients to afford the treatment. The U.S.-Israeli company said on Tuesday it will focus on completing its advanced study for NurOwn in patients with amyotrophic lateral sclerosis (ALS) as quickly as possible. U.S. Congress last month approved the RTT bill that would allow terminally ill patients to try experimental treatments not yet approved by the Food and Drug Administration.

  • The ‘Right to Try’ Could Cost Dying Patients a Fortune
    Bloomberg11 months ago

    The ‘Right to Try’ Could Cost Dying Patients a Fortune

    A small biotechnology company may be the first to offer dying patients unproven drugs under a new U.S. law called Right to Try that deregulated access to such experimental treatments. While details are still being worked out, the company’s chief executive officer pointed to the price of bespoke cell therapies used to treat cancer that cost more than $300,000. “Companies cannot be NGOs,” the nongovernmental organizations that help provide care to impoverished countries, Brainstorm CEO Chaim Lebovits said in a phone interview.

  • Should You Worry About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) CEO Pay?
    Simply Wall St.last year

    Should You Worry About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) CEO Pay?

    Chaim Lebovits is the CEO of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), which has recently grown to a market capitalization of US$91.73M. Recognizing whether CEO incentives are aligned with shareholders isRead More...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes